FDA approves belzutifan‑pembrolizumab combo for high‑risk kidney cancer

The U.S. Food and Drug Administration has approved the combination of belzutifan, a HIF‑2α inhibitor, and pembrolizumab, a PD‑1 inhibitor, as an adjuvant treatment for patients with high‑risk clear‑cell renal cell carcinoma who have undergone nephrectomy. The approval follows the LITESPARK‑022 trial, which showed a 28% reduction in the risk of disease recurrence or death compared with placebo.

The regimen targets residual cancer cells after surgery by blocking tumor adaptation to low‑oxygen environments and enhancing the immune system’s ability to destroy remaining malignant cells. The decision expands therapeutic options for a patient group that previously faced limited adjuvant choices, shifting care toward earlier use of combination therapies to prevent metastasis. Physicians will need to monitor side‑effects associated with both agents, such as fatigue, rash, and immune‑mediated reactions, as part of post‑surgical management.